Inhibrx Biosciences
INBX
68.97
-5.36
-7.21%
Inhibrx Biosciences
US · INBX
#3022 by market cap
Listed 2024
68.97
-5.36
-7.21%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:30
Recent news
-
Earnings Flash (INBX) Inhibrx Biosciences, Inc. Reports Q3 Revenue $2.0MMT Newswires · 2026/11/14
-
Rating change
Stifel Maintains Inhibrx Biosciences(INBX.US) With Buy Rating, Raises Target Price to $300Market Newswire · 2026/4/22
-
Analysts Offer Insights on NA Companies: Evommune, Inc. (EVMN), Inhibrx Biosciences Inc (INBX) and Circle Internet Group, Inc. Class A (CRCL)TipRanks · 2026/9/9
-
Rating change
LifeSci Capital Maintains Inhibrx Biosciences(INBX.US) With Buy Rating, Maintains Target Price $230Market Newswire · 2026/9/8
-
Rating change
Stifel Initiates Inhibrx Biosciences(INBX.US) With Buy Rating, Announces Target Price $150Market Newswire · 2026/4/17
-
Rating change
JMP Securities Maintains Inhibrx Biosciences(INBX.US) With Hold RatingMarket Newswire · 2025/3/19
-
H.C. Wainwright Maintains Inhibrx Biosciences(INBX.US) With Buy Rating, Maintains Target Price $245Market Newswire · 2026/9/9
-
Rating change
LifeSci Capital Maintains Inhibrx Biosciences(INBX.US) With Buy Rating, Raises Target Price to $230Market Newswire · 2026/5/11
-
Rating change
LifeSci Capital Initiates Inhibrx Biosciences(INBX.US) With Buy Rating, Announces Target Price $200Market Newswire · 2026/4/24
-
Company notice
Inhibrx: Inhibrx, Inc. - Distribution Option Symbol: INBX New Symbol: INBX1OCC · 2024/5/30
-
Rating change
LifeSci Capital Maintains Inhibrx Biosciences(INBX.US) With Buy Rating, Maintains Target Price $200Market Newswire · 2026/4/26
-
Rating change
Citizens JMP Maintains Inhibrx Biosciences(INBX.US) With Hold RatingMarket Newswire · 2025/5/16
-
Rating change
Analysts Have Conflicting Sentiments on These Healthcare Companies: Apellis Pharmaceuticals (APLS), Fractyl Health, Inc. (GUTS) and Inhibrx Biosciences Inc (INBX)TipRanks · 2026/5/11
-
Rating change
Analysts Are Bullish on These Healthcare Stocks: Structure Therapeutics, Inc. Sponsored ADR (GPCR), Inhibrx (INBX)TipRanks · 2023/11/20
-
Stifel Maintains Inhibrx Biosciences(INBX.US) With Buy Rating, Maintains Target Price $325Market Newswire · 2026/10/29
-
H.C. Wainwright Initiates Inhibrx Biosciences(INBX.US) With Buy Rating, Announces Target Price $245Market Newswire · 2026/8/25
-
Rating change
Stifel Maintains Inhibrx Biosciences(INBX.US) With Buy Rating, Raises Target Price to $325Market Newswire · 2026/5/15
-
Stifel Maintains Inhibrx Biosciences(INBX.US) With Buy Rating, Maintains Target Price $325Market Newswire · 2026/8/21
Headlines are aggregated automatically and are not independently verified or edited by our team.
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Inhibrx Biosciences discussion 0 comments